Arsenic Trioxide

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Trisenox; Belgium: Trisenox; Bulgaria: Trisenox; Cyprus: Trisenox; Czech Republic: Trisenox; Estonia: Trisenox; France: Trisenox; Germany: Trisenox; Greece: Trisenox; Hungary: Trisenox; Ireland: Trisenox; Italy: Trisenox; Latvia: Trisenox; Lithuania: Trisenox; Luxembourg: Trisenox; Malta: Trisenox; Netherlands: Trisenox; Poland: Trisenox; Portugal: Trisenox; Romania: Trisenox; Slovakia: Trisenox; Slovenia: Trisenox; Spain: Trisenox; Sweden: Trisenox; UK: Trisenox.

North America

USA: Trisenox.


Japan: Trisenox.

Drug combinations


Arsenic Trioxide: As~2~O~3~. Mw: 197.84. Diarsenic trioxide. CAS-1327-53-3 (2001).

Pharmacologic Category

Other Antineoplastic Agents. (ATC-Code: L01XX27).

Mechanism of action

Causes in vitro morphological changes and DNA fragmentation to NB4 human promyelocytic leukemia cells. Damages/degrades the fusion protein PML-RAR-α.

Therapeutic use

Induction of remission and consolidation in relapsed or refractory acute promyelocytic leukemia.

Pregnancy and lactiation implications

Crosses the human placenta. Pregnancy should be avoided. Not recommended during lactation.

Unlabeled use

Treatment of myelodysplastic syndrome, multiple myeloma.


Hypersensitivity to arsenic or any component of the formulation.

Warnings and precautions

Hazardous agent. May cause retinoic-acid-acute promyelocytic leukemia syndrome or APL differentiation syndrome (dyspnea, fever, weight gain, pulmonary infiltrates, and pleural or pericardial effusions) in acute promyelocytic leukemia. Risk of hyperleukocytosis. May prolong the QT interval. May lead to torsade de pointes or complete AV block. May produce electrolyte imbalances. Use with caution in renal impairment (renal excretion).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart